europharma rachtan sp. z o.o.

What europharma rachtan sp. z o.o. does

Europharma Sp. z o.o. is a privately held Contract Research Organization (CRO) founded in 2001 and headquartered in Katowice, Poland. The company provides clinical research and pharmacovigilance services to pharmaceutical companies, with a particular focus on post-authorization activities. Core service lines include Phase I–IV clinical trial management, post-authorization safety studies (PASS), post-authorization efficacy studies (PAES), drug utilization studies (DUS), non-interventional observational studies, pharmacovigilance operations (adverse drug reaction collection, CIOMS form preparation, international press monitoring, SOP preparation, and PV audits/training), registration support for pharmaceutical preparations and medical devices, and organization of medical conferences and training. Underlying technology assets include an internal CRM platform for managing clinical operations and an EU co-created independent ADR reporting platform (dzialanianiepozadane.com / adrreporting.com) that allows physicians, pharmacists, nurses, and patients to submit adverse drug reaction reports.

The business operates as a B2B professional services CRO targeting primarily pharmaceutical companies, with disclosed enterprise relationships with 6 of the Top 20 Global Pharma companies. Pricing is project-based and not publicly disclosed. The company positions itself as a flexible, alternative CRO to the largest global providers, emphasizing legal security, EMA regulatory compliance, and procedures developed in collaboration with leading Polish pharmaceutical law firms. Operations span Central Europe, supported by a multilingual web presence (Polish, English, Russian, Ukrainian), a professional team of over 30 specialists, and a cumulative track record of nearly 300 studies, approximately 50,000 contracted investigators, and over 1.2 million patients enrolled across nearly all therapeutic areas. No parent company, external funding rounds, or investor backing have been disclosed.

Name

europharma rachtan sp. z o.o.

Legal name

Europharma Sp. z o.o.

Website

https://europharma.edu.pl

Company type

Private

Founded year

2001

Operating status

Operating

Short description

Europharma Sp. z o.o. is a privately held Polish Contract Research Organization providing Phase I–IV clinical trials, PASS/PAES/DUS studies, non-interventional research, and pharmacovigilance services to pharmaceutical companies, including 6 of the Top 20 Global Pharma firms.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO)

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH)

akta.pro secondary industries

Clinical CROs (Phase I–IV) (HLAGAAAA), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)

Keywords

• Contract research organization
• Clinical research services
• Pharmacovigilance services
• Post-authorization safety studies
• Drug utilization studies

Headquarters

HQ city

Katowice

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Clinical Research Services: Professional services revenue from conducting clinical trials (Phase I-IV), PASS, PAES, DUS studies, and non-interventional observational studies for pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Europharma Sp. z o.o. is a Contract Research Organization (CRO) that conducts clinical research, post-authorization safety studies (PASS), post-authorization efficacy studies (PAES), drug utilization studies (DUS), and non-interventional observational studies for pharmaceutical companies. The firm also provides pharmacovigilance services, including adverse drug reaction (ADR) collection and analysis, and supports the registration of pharmaceutical preparations and medical equipment on the Polish market. The company operates from Katowice, Poland, with a team of over 30 specialists and has conducted nearly 300 studies involving approximately 50,000 investigators and over 1.2 million patients.

Product overview

Europharma Sp. z o.o. is a Contract Research Organization (CRO) offering a comprehensive suite of pharmaceutical research and pharmacovigilance services. The core offerings include Clinical Research (Phase I-IV trials), PASS/PAES/DUS Studies, Non-interventional Observational Studies, and Pharmacovigilance Services. Supporting these are the ADR Reporting Platforms (dzialanianiepozadane.com and adrreporting.com) for adverse drug reaction collection, a CRM Platform for operational management, and Conferences/Training services. The company operates primarily in Poland, supporting pharmaceutical companies in post-authorization safety monitoring and market research across nearly all therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Research (Phase I-IV)
• PASS/PAES/DUS Studies
• Non-interventional Observational Studies
• Pharmacovigilance Services
• Conferences, Congresses and Training
• ADR Reporting Platform

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• European UnioncoreStrategic or Co-development Partner · 1 January 2014Europharma collaborated with the European Union to create an independent internet platform (www.adrreporting.com, www.dzialanianiepozadane.com) for adverse drug reaction reporting. EU funding enabled the creation of this platform allowing patients, pharmacists, and healthcare professionals to quickly report adverse reactions to medicinal products, dietary supplements, or medical devices. The initiative was driven by Poland's low ADR reporting rate (only 0.02% of WHO reports in 2013).

Scale indicators8 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Premier Research: Mid-size CRO with strong post-marketing and pharmacovigilance offerings serving small and mid-cap pharma, comparable to Europharma's positioning as a flexible alternative to larger CROs.
• Ergomed plc: European-headquartered CRO with a strong pharmacovigilance and post-marketing safety services arm, directly comparable to Europharma's PASS/PAES specialization and EU regulatory focus.
• PSI CRO AG: Privately held European mid-size CRO with full-service clinical and post-marketing capabilities, serving global pharma from a regional European base — directly comparable in profile and client type to Europharma.
• Worldwide Clinical Trials: Mid-size global CRO offering clinical and post-authorization safety studies, comparable in scale and therapeutic-area breadth to Europharma, with similar positioning against mega-CROs.

Broad incumbents

• Syneos Health: Large global biopharmaceutical solutions organization with clinical and post-marketing service lines; relevant incumbent peer competing for Top 20 pharma post-authorization study outsourcing.
• Medpace Holdings: Mid-size publicly traded global CRO with full-service clinical trial capabilities; comparable in mid-size CRO positioning though operating at significantly larger scale and broader scope than Europharma.
• ICON plc: One of the largest global CROs post-PRA Health Sciences acquisition, offering comprehensive clinical and post-marketing services; a relevant incumbent benchmark for what Europharma competes against for pharma outsourcing budgets.
• IQVIA: The largest global CRO with end-to-end clinical, real-world evidence, and pharmacovigilance offerings; the dominant incumbent whose scale and integrated technology platform Europharma explicitly differentiates against.
• Charles River Laboratories: Global CRO with a dedicated Safety Assessment and pharmacovigilance-adjacent business, providing a relevant scaled-peer reference for Europharma's PASS/PAES/DUS specialization.
• Parexel International: Large global CRO (private since EQT/Goldman Sachs take-private) with strong post-marketing and pharmacovigilance services; a relevant incumbent peer competing for the same pharma client budgets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/europharma-m.rachtan-sp.-z-o.o.

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about europharma rachtan sp. z o.o.